Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Clinical Trials Network Task Force report

References

• Ochalek TA, Cumpston KL, Wills BK, Gal TS, Moeller FG. Nonfatal opioid overdoses at an urban emergency department during the COVID-19 pandemic. JAMA. 2020;324(16):1673–1674.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews. 2014;38(2):14–23.
   PubMed Web of Science ®Google Scholar
• Mojtabai R, Mauro C, Wall MM, Barry CL, Olfson M. Medication treatment for opioid use disorders in substance use treatment facilities. Health Aff (Millwood). 2019;38(1):14–23.
   PubMed Web of Science ®Google Scholar
• Joudrey PJ, Edelman EJ, Wang EA. Drive times to opioid treatment programs in urban and rural counties in 5 US states. JAMA. 2019;322(13):1310–1312.
   PubMed Web of Science ®Google Scholar
• Alderks CE. Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment facilities: 2003–2015 (update). In: The CBHSQ report. Rockville, MD: Substance Abuse and Mental Health Services Administration (US); 2013. Accessed June 9, 2021. http://www.ncbi.nlm.nih.gov/books/NBK469748/
   Google Scholar
• Joudrey PJ, Chadi N, Roy P, et al. Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study. Drug Alcohol Depend. 2020;211:107968.
   PubMed Web of Science ®Google Scholar
• Kleinman RA. Comparison of driving times to opioid treatment programs and pharmacies in the US. JAMA Psychiatry. 2020;77(11):1163–1171. Published online July 15.
   PubMed Web of Science ®Google Scholar
• Hansen H, Siegel C, Wanderling J, DiRocco D. Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City. Drug Alcohol Depend. 2016;164:14–21.
   PubMed Web of Science ®Google Scholar
• Pro G, Zaller N. Interaction effects in the association between methadone maintenance therapy and experiences of racial discrimination in U.S. healthcare settings. Plos One. 2020;15(2):e0228755.
   PubMed Web of Science ®Google Scholar
• Manhapra A, Quinones L, Rosenheck R. Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration. Drug Alcohol Depend. 2016;160:82–89.
   PubMed Web of Science ®Google Scholar
• Goedel WC, Shapiro A, Cerdá M, Tsai JW, Hadland SE, Marshall BDL. Association of racial/ethnic segregation with treatment capacity for opioid use disorder in counties in the United States. JAMA Netw Open. 2020;3(4):e203711.
   PubMed Web of Science ®Google Scholar
• Jones ES, Fiellin DA. Women and opioid dependence treatment: office-based versus opioid treatment program-based care?. Subst Abus. 2007;28(2):3–8.
   PubMedGoogle Scholar
• Mattocks KM, Clark R, Weinreb L. Initiation and engagement with methadone treatment among pregnant and postpartum women. Womens Health Issues. 2017;27(6):646–651.
   PubMed Web of Science ®Google Scholar
• Patrick SW, Richards MR, Dupont WD, et al. Association of pregnancy and insurance status with treatment access for opioid use disorder. JAMA Netw Open. 2020;3(8):e2013456.
   PubMed Web of Science ®Google Scholar
• Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2021;26(1):30–39. Published online September 14, 10.
   PubMed Web of Science ®Google Scholar
• Kelley AT, Dungan MT, Gordon AJ. Barriers and facilitators to buprenorphine prescribing for opioid use disorder in the Veterans Health Administration During COVID-19. J Addict Med. 2020;4:413–418.
   PubMedGoogle Scholar
• Gustavson AM, Gordon AJ, Kenny ME, et al. Response to coronavirus 2019 in Veterans Health Administration facilities participating in an implementation initiative to enhance access to medication for opioid use disorder. Subst Abus. 2020;41(4):413–418.
   PubMed Web of Science ®Google Scholar
• Peavy KM, Darnton J, Grekin P, et al. Rapid implementation of service delivery changes to mitigate COVID-19 and maintain access to methadone among persons with and at high-risk for HIV in an opioid treatment program. AIDS Behav. 2020;24(9):2469–2472.
   PubMed Web of Science ®Google Scholar
• Joudrey PJ, Adams ZM, Bach P, et al. methadone access for opioid use disorder during the COVID-19 pandemic within the United States and Canada. JAMA Netw Open. 2021;4(7):e2118223.
   PubMed Web of Science ®Google Scholar
• Amram O, Amiri S, Thorn EL, Lutz R, Joudrey PJ. Changes in methadone take-home dosing before and after COVID-19. J Subst Abuse Treat. Published online June 24, 2021;108552.
   PubMedGoogle Scholar
• SAMHSA. Opioid Treatment Program (OTP) Guidance. Published 2020. https://www.samhsa.gov/sites/default/files/otp-guidance-20200316.pdf.
   Google Scholar
• Davis CS, Samuels EA. Opioid policy changes during the COVID-19 pandemic - and beyond. J Addict Med. 2020;14(4):e4–e5. Published online May 20.
   PubMed Web of Science ®Google Scholar
• Drug Enforcement Adminstration. COVID-19 information page. Diversion Control Division. Accessed April 6, 2021. https://www.deadiversion.usdoj.gov/coronavirus.html.
   Google Scholar
• Hunter SB, Dopp AR, Ober AJ, Uscher-Pines L. Clinician perspectives on methadone service delivery and the use of telemedicine during the COVID-19 pandemic: a qualitative study. J Subst Abuse Treat. 2021;124:108288.
   PubMed Web of Science ®Google Scholar
• Courtwright DT. Dark paradise. Cambridge, MA: Harvard University Press; 2009.
   Google Scholar
• Jaffe JH, O’Keeffe C. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend. 2003;70(2 Suppl):S3–S11.
   PubMedGoogle Scholar
• McCarty D, Priest KC, Korthuis PT. Treatment and prevention of opioid use disorder: challenges and opportunities. Annu Rev Public Health. 2018;39(1):525–541.
   PubMed Web of Science ®Google Scholar
• Leshner AI, Mancher M. Medications for opioid use disorder save lives. National Academies of Sciences, Enginneering, and Medicine. Published online 2019.
   Google Scholar
• Calcaterra SL, Bach P, Chadi A, et al. Methadone matters: what the United States can learn from the global effort to treat opioid addiction. J Gen Intern Med. 2019;34(6):1039–1042.
   PubMed Web of Science ®Google Scholar
• SAMHSA. Federal Guidelines for Opioid Treatment Programs. 2015. https://store.samhsa.gov/sites/default/files/d7/priv/pep15-fedguideotp.pdf.
   Google Scholar
• Joudrey PJ, Edelman EJ, Wang EA. Methadone for opioid use disorder-decades of effectiveness but still miles away in the US. JAMA Psychiatry. 2020;77(11):1105–1106. Published online July 15.
   PubMed Web of Science ®Google Scholar
• GovRegs.com. 42 CFR 8.12 - Federal opioid treatment standards. Accessed November 4, 2020. https://www.govregs.com/regulations/expand/title42_chapterI_part8_subpartC_section8.12#title42_chapterI_part8_subpartC_section8.12.
   Google Scholar
• Korthuis PT, McCarty D, Weimer M, et al. Primary care-based models for the treatment of opioid use disorder: a scoping review. Ann Intern Med. 2017;166(4):268–278.
   PubMed Web of Science ®Google Scholar
• Jin H, Marshall BD, Degenhardt L, et al. Global opioid agonist treatment: a review of clinical practices by country. Addiction. 2020;115(12):2243–2254.
   PubMed Web of Science ®Google Scholar
• Priest KC, Gorfinkel L, Klimas J, Jones AA, Fairbairn N, McCarty D. Comparing Canadian and United States opioid agonist therapy policies. Int J Drug Policy. 2019;74:257–265.
   PubMed Web of Science ®Google Scholar
• Nolan S, Hayashi K, Milloy M-J, et al. The impact of low-threshold methadone maintenance treatment on mortality in a Canadian setting. Drug Alcohol Depend. 2015;156:57–61.
   PubMed Web of Science ®Google Scholar
• Knopf A. DEA proposal for mobile methadone finally released. Alcohol Drug Abuse Weekly. 2020;32(46):3–4.
   Google Scholar
• Novick DM, Salsitz EA, Joseph H, Kreek MJ. Methadone medical maintenance: an early 21st-century perspective. J Addict Dis. 2015;34(2-3):226–237.
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services. Methadone maintenance in primary care program. Published online 2000. https://www.samhsa.gov/sites/default/files/programs_campaigns/medication_assisted/dear_colleague_letters/2000-colleague-letter-methadone-medical-maintenance.pdf.
   Google Scholar
• Wu LT, John WS, Morse E, et al. Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasbility clinical trial. Addiction. 2021.
   Google Scholar
• Zerhouni E. The NIH roadmap. Am Assoc Adv Sci. 2003;302(5642):63–72.
   Google Scholar
• Williams AR, Nunes EV, Bisaga A, et al. Developing an opioid use disorder treatment cascade: a review of quality measures. J Subst Abuse Treat. 2018;91:57–68.
   PubMed Web of Science ®Google Scholar
• Brooklyn JR, Sigmon SC. Vermont hub-and-spoke model of care for opioid use disorder: development, implementation, and impact. J Addict Med. 2017;11(4):286–292.
   PubMed Web of Science ®Google Scholar
• Gliklich RE, Dreyer NA, Leavy MB, Christian JB. 21 st Century patient registries: registries for evaluating patient outcomes: a user’s guide: Addendum [Internet]. Published online 2018.
   Google Scholar
• Karnik NS, Campbell CI, Curtis ME, et al. Core outcomes set for research on the treatment of opioid use disorder (COS-OUD): the National Institute on Drug Abuse Clinical Trials Network protocol for an e-Delphi consensus study. Trials. 2021;22(1):102.
   PubMed Web of Science ®Google Scholar
• Hser Y-I, Saxon AJ, Huang D, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79–87.
   PubMed Web of Science ®Google Scholar
• Lee JD, Nunes EV Jr, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): a multicentre, open-label, randomised controlled trial. The Lancet. 2018;391(10118):309–318.
   PubMed Web of Science ®Google Scholar
• Tanum L, Solli KK, Latif Z-H, et al. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiatry. 2017;74(12):1197–1205.
   PubMed Web of Science ®Google Scholar
• Nunes EV, Scodes JM, Paylicova M, et al. Sublingual buprenorphine/naloxone versus injection naltrexone for opioid use disorder: can patient characteristics guide choice of treatment? American Journal of Psychiatry. Published Online in Press.
   Google Scholar
• Nunes EV, Kunz K, Galanter M, O’Connor PG. Addiction psychiatry and addiction medicine: the evolution of addiction physician specialists. Am J Addict. 2020;29(5):390–400.
   PubMed Web of Science ®Google Scholar
• SAMHSA. A national assessment of methadone-associated mortality: background briefing report. Published online 2004. http://www.legalsideofpain.com/uploads/methadone_mortality_briefing.pdf.
   Google Scholar
• Slavova S, Delcher C, Buchanich JM, Bunn TL, Goldberger BA, Costich JF. Methodological complexities in quantifying rates of fatal opioid-related overdose. Curr Epidemiol Rep. 2019;6(2):263–274.
   PubMedGoogle Scholar